KELIX bio’s Hocine Sidi-Saïd: “We are looking closely at Algeria for an acquisition at the end of 2022”
The head of the pharmaceutical platform launched with DPI funding talked to Africa Business+ after the takeover of PHI, his first operation in Morocco.
28/03/2022 at 15h44, by Africa Business+
Initially named Zanzibar Pharma, KELIX Bio was launched in 2020 by London-based fund manager Development Partners International (DPI) with the support of CDC and the EBRD. Based in Dubai, the company, which is looking to expand into generic manufacturing, has raised a total of $750 million for its international development. CDC has a 40% stake in the company, with the EBRD and DPI each holding 30%.
Recommended articles
Industry
16/03/2022 at 16h41, by Africa Business+
DPI submits bid for Solevo, OCP drops out after all
Inside information from Africa Business+.
Telecoms
10/02/2022 at 19h00, by Africa Business+
CDC, DEG and EAIF join IFC Axian $420 million fundraising
More information from Africa Business+.
Health
03/11/2021 at 17h49, by Africa Business+
Sahel Pharma Industrie launches pharmaceutical manufacturing project
According to Africa Business+ sources, the Burkinabe pharmaceutical group has raised CFAF 10.5 billion...
Bank
15/07/2021 at 13h56, by Africa Business+
UK’s CDC Group provides $50 million facility for Ecobank
With a strong presence in financial services in East and Southern Africa, the British institution of...
Health
25/09/2020 at 17h03, by Africa Business+
Medical Credit Fund (PharmAccess) considers Senegal and Côte d’Ivoire with the help of CDC
Amid the Covid-19 crisis, the private clinics-focused investment fund intends to broaden its horizons,...